BioNTech to acquire antibody rights, ADC tech from CellmAbs

DNY59 BioNTech ( NASDAQ: BNTX ) has entered into a patent assignment and license agreement to acquire one of CellmAbs’ pre clinical antibody candidates and additional ADC technology, a deal that could be worth around a billion dollars, according to CellmAbs. Under the deal, CellmAbs will receive upfront and near term payments and could be eligible to receive “several hundred million US Dollars" in milestone payments, plus tiered royalty payments, according to a CellmAbs statement released earlier this week.

Based in Portugal, CellmAbs was spun out of NOVA University of Lisbon in 2019. CellmAbs said the BioNTech deal could mark “Portugal’s first billion dollar transaction in the life sciences sector.” Financial details were not disclosed. BioNTech released its preliminary 2023 financial results , 2024 revenue forecast and a business update at the annual JP Morgan Healthcare Conference earlier this week.

More on BioNTech BioNTech SE (BNTX) 42nd Annual J.P. Morgan Healthcare Conference (Transcript) BioNTech's Strategic Shift: Diversifying Into Cancer Therapeutics BioNTech's COVID 19 Success Paves The Way For A Strong Drug Pipeline WuXi, BioNTech sign deal for monoclonal antibody discovery BioNTech sets 2024 outlook below consensus.